Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1980 1
1988 1
1989 1
1992 1
1993 3
1994 2
1995 5
1996 4
1997 3
1998 8
1999 11
2000 13
2001 14
2002 10
2003 8
2004 11
2005 15
2006 20
2007 20
2008 13
2009 17
2010 17
2011 15
2012 12
2013 11
2014 10
2015 16
2016 19
2017 13
2018 23
2019 15
2020 22
2021 25
2022 33
2023 25
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

406 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2023 Dec 28:S0161-6420(23)00933-8. doi: 10.1016/j.ophtha.2023.12.026. Online ahead of print. Ophthalmology. 2023. PMID: 38158159 Free article.
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
Catalytic enantioselective aldol reactions.
Yamashita Y , Yasukawa T , Yoo WJ , Kitanosono T , Kobayashi S . Yamashita Y , et al. Among authors: yasukawa t. Chem Soc Rev. 2018 Jun 18;47(12):4388-4480. doi: 10.1039/c7cs00824d. Chem Soc Rev. 2018. PMID: 29845124 Review.
Drug delivery from ocular implants.
Yasukawa T, Ogura Y, Kimura H, Sakurai E, Tabata Y. Yasukawa T, et al. Expert Opin Drug Deliv. 2006 Mar;3(2):261-73. doi: 10.1517/17425247.3.2.261. Expert Opin Drug Deliv. 2006. PMID: 16506952 Review.
Drug targeting to choroidal neovascularization.
Kimura H, Yasukawa T, Tabata Y, Ogura Y. Kimura H, et al. Among authors: yasukawa t. Adv Drug Deliv Rev. 2001 Oct 31;52(1):79-91. doi: 10.1016/s0169-409x(01)00190-9. Adv Drug Deliv Rev. 2001. PMID: 11672877 Review.
Drug delivery systems for vitreoretinal diseases.
Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y. Yasukawa T, et al. Prog Retin Eye Res. 2004 May;23(3):253-81. doi: 10.1016/j.preteyeres.2004.02.003. Prog Retin Eye Res. 2004. PMID: 15177203 Review.
406 results